The Rx Consultant 

New Drugs 2018


This CE activity was originally published in The Rx Consultant.  If you received credit for it previously, you cannot receive credit for it again.

In 2018, the US Food and Drug Administration (FDA) approved 59 new drugs – the highest number in more than 10 years – including 19 first-in-class agents.

Of the 59 new approvals, 73% received priority review. This issue of The Rx Consultant focuses on the new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: influenza infection, HIV-1 infection, pneumonia and skin infections, nonmetastatic, castration-resistant prostate cancer, endometriosis, migraine prophylaxis, moderate to severe acne, and chronic, idiopathic constipation.

Dosing and drug interactions are detailed in Table 1. Brief descriptions of selected additional new drugs are shown in Table 2, and new HIV drugs and HIV drug combinations are decribed in Table 3. Table 4 lists selected new formulations or indications for previously approved drugs.

Format
This CE activity is a monograph (PDF file).

 

Fee

$10.00

CE Hours

2.00

CE Units

0.200

Activity Type

Knowledge

Target Audience(s)

Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses

Accreditation(s)

This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.

CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours.  CE credit is automatically reported to CPE Monitor.
 
CE activities for Nurse Practitioners and Clinical Nurse Specialists: 
    This continuing education activity meets the requirements of:
        The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
        The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
 
    This is a pharmacotherapeutics/pharmacology CE activity.
  • The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
  • Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.  
  • Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
 
 
Accreditation Council for Pharmacy Education
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

To receive CE credit, the participant must read the monograph in its entirety, complete the online post-test and receive a score of 70% or greater, and complete the online evaluation.
 
Pharmacists and Pharmacy Technicians -
 
Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits cannot be reported to CPE Monitor.
 
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation are successfully completed.

 

 

Objectives

  • For each of the drugs reviewed: 1. List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy.
  • 2. Describe significant side effects and drug interactions. Provide 2-3 patient counseling tips.
  • For drugs listed in Tables 2 and 3: 3. List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.

Speaker(s)/Author(s)

James Chan, Pharm.D., PhD


Brief Bio : James Chan, PharmD, PhD, Pharmacy Quality and Outcomes Coordinator, Kaiser Permanente, Oakland, CA and Associate Clinical Professor, School of Pharmacy, University of California, San Francisco, CA.

Pamela Mausner, MD


Brief Bio : Pamela Mausner, MD; Medical Writer/Editor and Healthcare Advocate; and Associate Editor, The Rx Consultant.

Activity Number

0428-0000-19-005-H01-P

Release Date: Mar 22, 2019
Credit Expiration Date: Mar 22, 2022

CE Hours

2.00

Fee

$10.00